Robert W. Simms, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Dept of Medicine
Rheumatology

MD, University of Rochester School of Medicine & Dentistry



Dr. Simms is Emeritus Professor of Rheumatology at Chobanian and Avedisian School of Medicine. His major research interest is in scleroderma clinical outcome measures and clinical trials. He is the most active scleroderma clinician in the section, and is the site PI on multiple past and ongoing multicenter trials. He partners with Dr. Lafyatis in clinical and translational studies. This has included a recently completed trial of rituximab in systemic sclerosis. He works very closely with Dr. Farber on clinical issues as well as clinical trial initiatives in pulmonary hypertension. Dr. Simms receives NIH support as the site PI on a multi-center trial of high dose immunosuppressive therapy and autologous bone marrow transplant compared to cyclophosphamide (SCOT).

Member
Boston University
Arthritis & Autoimmune Diseases Research Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
05/23/2019 - 03/31/2023 (PI)
Corbus Pharmaceuticals Holdings, Inc.


Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
09/22/2017 - 08/31/2022 (Subcontract PI)
University of Pittsburgh NIH NIAMS
5P50AR060780-07

Protocol #201247, A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics pharmacodyna
08/30/2017 - 08/29/2022 (PI)
GlaxoSmithKline LLC


A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B (TGFB) Inhibitor, in Patients with Diffuse Cutaneous Systemic
02/25/2019 - 02/24/2022 (PI)
Formation Biologics Corp.


Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 01/31/2022 (PI of Sub-Project / SP)
Benaroya Research Institute at Virginia Mason NIH NIAID
2UM1AI109565-08

OPsumit Historical USers cohort study (OrPHeUS). a Multicenter. retrospective chart review of first-time Opsumit® (macitentan) users in the United States
02/06/2018 - 12/31/2021 (PI)
Actelion Pharmaceuticals, Ltd.


United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2021 (PI)
United States Pulmonary Hypertension Scientific Registry


US-based, observation, drug registry of Opsumit (macitentan) new users in clinical practice
01/16/2015 - 12/08/2021 (PI)
Actelion Pharmaceuticals, Ltd.


A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2021 (PI)
Corbus Pharmaceuticals Holdings, Inc.


A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis
04/05/2016 - 04/30/2020 (PI)
Genentech, Inc.


Showing 10 of 49 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2015 NIAMS: CORT 5P50AR060780-05 80
2015 Rheumatic Diseases Research Core Centers 5P30AR061271-05 52
2015 Core B Clinical Core 5P50AR060780-05-7136 80
2013 Core B Clinical Core 5P50AR060780-03-7136 80

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Shah A, Storek J, Woolson R, Pinckney A, Keyes-Elstein L, Wallace PK, Sempowski GD, McSweeney P, Mayes MD, Crofford L, Csuka ME, Phillips K, Khanna D, Simms R, Ballen K, LeClercq S, Clair WS, Nixon AB, Nash R, Wener M, Brasington R, Silver R, Griffith LM, Furst DE, Goldmuntz E, Sullivan KM. Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology (Oxford). 2022 10 06; 61(10):4155-4162. PMID: 35108379; PMCID: PMC9536786; DOI: 10.1093/rheumatology/keac015;
     
  2. Khanna D, Caldron P, Martin RW, Kafaja S, Spiera R, Shahouri S, Shah A, Hsu V, Ervin J, Simms R, Domsic RT, Steen V, Hummers LK, Derk C, Mayes M, Chatterjee S, Varga J, Kesten S, Fraser JK, Furst DE. Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis Rheumatol. 2022 Aug; 74(8):1399-1408. PMID: 35358372; PMCID: PMC9544105; DOI: 10.1002/art.42133;
     
  3. Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Lafyatis R. Correction: Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2022 May 23; 24(1):118.View Related Profiles. PMID: 35606822; PMCID: PMC9125924; DOI: 10.1186/s13075-022-02816-8;
     
  4. Keyes-Elstein L, Pinckney A, Goldmuntz E, Welch B, Franks JM, Martyanov V, Wood TA, Crofford L, Mayes M, McSweeney P, Nash R, Georges G, Csuka ME, Simms R, Furst D, Khanna D, Clair EWS, Whitfield ML, Sullivan KM. Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care Res (Hoboken). 2021 Sep 17. PMID: 34533286; PMCID: PMC8926930; DOI: 10.1002/acr.24785;
     
  5. Kong K, Koontz D, Morse C, Roth E, Domsic RT, Simon MA, Stratton E, Buchholz C, Tobin-Finch K, Simms R, George MP, Hassoun PM, Farber H, Lafyatis R. A Pilot Study of Dimethyl Fumarate in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. J Scleroderma Relat Disord. 2021 Oct 01; 6(3):242-246.View Related Profiles. PMID: 35005243; PMCID: PMC8741170; DOI: 10.1177/23971983211016196;
     
  6. Spiera R, Chung L, Frech T, Domsic R, Hsu V, Furst DE, Simms R, Mayes M, Martyanov V, Whitfield ML, Dgetluck N, Dinh Q, White B. Reply. Arthritis Rheumatol. 2021 04; 73(4):716-717. PMID: 33164325
     
  7. Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-Cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2020 Dec; 2(12):e743-e753.View Related Profiles. PMID: 34966900; PMCID: PMC8713509; DOI: 10.1016/s2665-9913(20)30237-x;
     
  8. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021 01; 159(1):311-327. PMID: 32858008; PMCID: PMC7803940; DOI: 10.1016/j.chest.2020.07.088;
     
  9. Simms RW. Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma. Arthritis Rheumatol. 2020 09; 72(9):1415-1426. PMID: 32562363
     
  10. Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020 08; 72(8):1350-1360.View Related Profiles. PMID: 32336038; PMCID: PMC7497006; DOI: 10.1002/art.41294;
     
Showing 10 of 104 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 104 publications over 32 distinct years, with a maximum of 8 publications in 1996 and 2014 and 2016

YearPublications
19882
19901
19913
19922
19931
19946
19952
19968
19983
19992
20001
20011
20024
20031
20041
20062
20073
20081
20095
20102
20112
20122
20134
20148
20154
20168
20175
20187
20193
20204
20213
20223

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Scleroderma
Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map


Simms's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department